Altria Group Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $23.5B-2.3% YoYTTM through 30 Jun 2026
Net Income $8B-29.2% YoYTTM through 30 Jun 2026
Free Cash Flow $9.1BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 63.0% |
| EBITDA Margin | 47.8% |
| Operating Margin | 46.8% |
| Net Margin | 34.0% |
Returns
-298.8%ROE
23.9%ROA
40.8%ROIC
Balance Sheet Health
Debt / Equity-9.21x
Current Ratio0.52x
Net Debt$22.2B
Cash & Equivalents$2.4B
Quality Metrics
Altman Z-Score5.09
Piotroski F-Score7 / 9
FCF Margin38.8%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $23.3B
Diluted EPS$4.75TTMFY2025: $4.12
Dividend
$2.12Per share, FY20263.09%Yield-9.6%5-yr growth
Capital Allocation
R&D Spend$195M
Capex Intensity1.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Smokeable Products | $20.5B | -3.4% | View detailsExpects continued pricing power to offset secular volume declines, with progressive increases in cigarette import and export activity over 2026. |
| Oral Tobacco Products | $2.8B | +0.9% | View detailsHelix received FDA marketing authorizations for on! PLUS in mint, wintergreen, and tobacco at 6mg and 9mg strengths, supporting nationwide expansion in 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.